Brief: Hansoh Pharmaceutical Transfers Kiomedinevsone License To Jiangsu Hengrui Pharmaceuticals
29/04/2026 13:34
April 29 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: TRANSFERS KIOMEDINEVSONE LICENSE TO JIANGSU HENGRUI PHARMACEUTICALS ON APRIL 29, 2026 TRANSFER PRICE FOR KIOMEDINEVSONE LICENSE SET AT RMB131 MILLION Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion